Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.75 |
| ▸ | FAAH | O00519 | 2/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25913032 | 0.98 | EPHX1 (0.79) | EPHX1FAAHEPHX2CASP2 | |
| SCHEMBL6047100 | 0.93 | EPHX1 (0.68) | EPHX1FAAHEPHX2 | |
| SCHEMBL9763831 | 0.91 | EPHX1 (0.75) | EPHX1FAAHEPHX2CASP2 | |
| SCHEMBL10645500 | 0.89 | EPHX1 (0.79) | EPHX1FAAHEPHX2CASP2 | |
| SCHEMBL9390 | 0.89 | EPHX1 (0.95) | EPHX1EPHX2CASP2 | |
| SCHEMBL25271304 | 0.86 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25275055 | 0.86 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25227881 | 0.86 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25230056 | 0.86 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25271007 | 0.86 | EPHX1 (1.00) | EPHX1EPHX2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163404-A1 | NOVEL UREA COMPOUNDS AND BIOISOSTERES THEREOF AND THEIR USE FOR TREATING INFLAMMATION AND INFLAMMATION-RELATED PATHOLOGIES | UNIVERSITé LAVAL (CA) | 2021-06-03 | — | — | US | disclosed |
| EP-1169303-B1 | ARYL-CHLOROALKYL UREAS | SOVAR (CA) | 2005-12-07 | — | — | EP | disclosed |
| US-20050250853-A1 | Beta-tubulin inhibitors | GAUDREAULT RENE C | 2005-11-10 | — | — | US | disclosed |
| WO-2004106291-A1 | HALOETHYL UREA COMPOUNDS AND THE USE THEREOF TO ATTENUATE, INHIBIT OR PREVENT CANCER CELL MIGRATION | IMOTEP INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004106292-A1 | HALOETHYL UREA COMPOUNDS AND THEIR USE TO ATTENUATE, INHIBIT OR PREVENT NON-CANCEROUS PATHOGENIC CELLULAR PROLIFERATION AND DISEASES ASSOCIATED THEREWITH | IMOTEP INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| US-20020115722-A1 | SS tubulin inhibitors | SOVAR, SOCIETE EN COMMANDITE (CA) | 2002-08-22 | — | — | US | disclosed |
| EP-1169303-A2 | NOVEL ARYL-CHLORO-ETHYL UREAS | Université Laval (CA) | 2002-01-09 | — | — | EP | disclosed |
| EP-1169303-A2 | NOVEL ARYL-CHLORO-ETHYL UREAS | Université Laval (CA) | 2002-01-09 | — | — | EP | disclosed |
| WO-2001047504-A2 | β-TUBELIN INHIBITORS AND THEIR USE AGAINST CANCER | UNIVERSITé LAVAL (CA) | 2001-07-05 | — | — | WO | disclosed |
| WO-2000061546-A3 | NOVEL ARYL-CHLORO-ETHYL UREAS | UNIV LAVAL (CA) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000061546-A2 | NOVEL ARYL-CHLORO-ETHYL UREAS | UNIVERSITE LAVAL (CA) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000061546-A2 | NOVEL ARYL-CHLORO-ETHYL UREAS | UNIVERSITE LAVAL (CA) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250853-A1 | Beta-tubulin inhibitors | TUBB, TUBB1, TUBB3 | EPHX1 3468/4885FAAH 3997/4885EPHX2 3704/4885 |
| US-20210163404-A1 | NOVEL UREA COMPOUNDS AND BIOISOSTERES THEREOF AND THEIR USE FOR TREATING INFLAMMATION AND INFLAMMATION-RELATED PATHOLOGIES | NOS3, NOS2, CBS | EPHX1 1279/4885FAAH 795/4885EPHX2 2509/4885 |
| US-20020115722-A1 | SS tubulin inhibitors | TUBB1, TUBB, TUBB3 | EPHX1 3357/4885FAAH 4175/4885EPHX2 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.